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Background. To examine the effect of plasminogen activator therapy on vascular permeability, we used a modified rabbit mesenteric model of extravascular tissue accumulation of radiolabeled albumin.
Methods and Results. Albumin deposition was measured after saline, tissue-type plasminogen activator (t-PA; 0.86 mg/kg for 1 hour followed by 0.29 mg/kg for 2 hours), or t-PA plus 1-deamino-8-D-arginine vasopressin (DDAVP; 0.6 mg/kg/hr for 30 minutes) infusion in animals with or without aspirin (ASA; 15-mg/kg bolus) pretreatment. In animals not given ASA, t-PA caused a 240% increase in tissue ['251 ]albumin accumulation over time (p<0.001). DDAVP prevented the rise in albumin accumulation normally seen with t-PA alone (p<0.05) in animals not given ASA. In animals pretreated with ASA, t-PA similarly caused an increase in tissue albumin accumulation, but this was significantly attenuated from that of animals not given ASA (p<0.03). Interestingly, DDAVP failed to block the response to t-PA in the animals given ASA. Because increases in vascular permeability correlated with increases in bleeding time (r=0.37, p<0.03), these data suggest that the effect of plasmin generation on vascular permeability may contribute to the bleeding tendency seen with thrombolytic therapy. The ability of DDAVP to reverse the bleeding tendency and bleeding time may be due in part to its reversal of the increased vascular permeability induced by the administration of plasminogen activators.
Conclusions. These data show that plasminogen activation causes an increase in vascular permeability that is inhibited by DDAVP; ASA blunts this action of t-PA and prevents the DDAVP blockade of the increase in permeability induced by t-PA in this rabbit model.
(Circulation 1991;84:2568-2573) A lthough thrombolytic agents benefit patients with acute myocardial infarction, these agents can also cause spontaneous bleeding, which can be a life-threatening side effect.1-3 The mechanism underlying the bleeding tendency produced by thrombolytic therapy is not clearly understood.
We recently reported that the bleeding tendency observed after streptokinase administration did not correlate with any of the recognized determinants of bleeding such as platelet function, hematocrit, fibrinogen levels, and von Willebrand factor concentration or multimer distribution but instead correlated with bleeding time.1 We therefore concluded from these observations that one possible parameter that could account for the bleeding diathesis of thrombolytic therapy is a compromise in vessel integrity. The present study was designed to examine this possibility using vascular permeability to albumin as an index of vascular integrity. We Bleeding Times Bleeding times were measured using previously described methods.14 Briefly, a shaved rabbit ear was placed into a 37°C water bath for 5 minutes to warm the ear. A full-thickness incision was made with a 15 stainless-steel surgical blade (Brad-Parker Becton Dickinson and Co., Lincoln Park, N.J.), with care taken to avoid any macroscopically visible vessels. The ear was returned to the saline bath and observed until all blood flow ceased. We also measured mesenteric bleeding times as described by Niewiarowski and colleagues.5 Microscopically visible veins on small bowel segments were cut and monitored for time to cessation of flow using gauze to collect the blood. Care was taken to avoid physical contact of the actual incision site during the bleeding time measurements.
Protocol
After surgery, the animals were allowed to recovery for 15-30 minutes before baseline blood samples were collected for plasmin activity determination (see Figure 1 ). Basal bleeding times were also measured. ASA was then given to the designated animals, and the animals were monitored for 1 hour before beginning the t-PA or saline infusion. In some animals, another bleeding time and blood sampling were obtained at the end of this incubation period. Saline or t-PA infusion was then begun, and a third bleeding time and blood sampling were performed at the end of the first hour of the t-PA infusion. It was at this point that radiolabeled albumin was injected into the -SMA cannula; tissue sampling was begun 5 minutes later (see above). Bleeding time and blood sampling were again performed at the second and third hours of t-PA or saline infusion.
Assays
Plasma plasmin activity was measured using a chromogenic substrate method as described previously.1'6 Plasma (50 ,l) was incubated at 37°C with 0. ments, we infused saline into the SMA to flush the tissue of intravascular blood. This was done immediately after the 120-minute sampling period, and tissue adjacent to the presaline washout sample was taken for comparison. We found no significant difference in tissue counts before or after the saline washout (232+48% versus 213±40%, n=3).
We also examined the effect of DDAVP on the vascular permeability changes seen after t-PA infusion. DDAVP, which was begun when the radiolabeled albumin bolus was injected, completely prevented the rise in tissue counts, with radioactivity accumulation being only 97+16%, 106±19%, and 110±22% of baseline at 30, 60, and 120 minutes, respectively. Figure 2B shows the vascular permeability responses to saline, t-PA, or t-PA plus DDAVP FIGURE 4. Scatterplot of regression analysis ofpermeability and plasma plasmin activity. Permeability at 2 hours after the start of tissue-type plasminogen activator or saline placebo is plotted against the corresponding plasma plasmin activity.
Discussion
Our results show that thrombolytic treatment causes an increase in vascular permeability as determined by extravascular radiolabeled albumin accumulation in mesenteric tissue. Adjunctive treatment with ASA did not prevent but significantly attenuated the permeability response to t-PA. DDAVP prevented the increase in tissue albumin accumulation after t-PA administration in animals not given ASA; however, DDAVP failed to do so in animals treated with ASA. We also demonstrate that permeability significantly correlated with bleeding time prolongation as well as with plasma plasmin activity.
One of the major side effects of thrombolytic therapy is spontaneous bleeding from nonsurgical as well as surgical sites. We have recently reported that bleeding noted in animals treated with a plasminogen activator correlated with bleeding time prolongation.' This association was independent of any change in platelet function, decrease in hematocrit or fibrinogen levels, or alterations in von Willebrand factor antigen or multimer distribution. Because we could not detect any significant contribution to bleeding risk by any of these major determinants of bleeding, we hypothesized that alterations in vascular integrity may explain our observations. Using vascular permeability to albumin as an index of vascular integrity, we examined the effect of thrombolysis on albumin deposition in extravascular intestinal tissue.
It is beyond the scope of the present study to describe the specific means by which thrombolytic agents lead to alterations in vessel wall integrity. We can only speculate at this point as to possible mechanisms by which t-PA and/or plasmin may act to alter permeability. Several investigators have shown that plasmin can lead to the generation of kinins and complement activation, both of which can directly or indirectly alter endothelial cell and vascular permeability.8 '9 In addition, certain proteolytic fragments of fibrin(ogen), such as Bl31-42, have also been shown to increase vascular permeability. 10 Another possibility involves the stimulation of platelets by plasmin, which then release agents that are capable of affecting endothelial permeability. For example, after infusion of thrombolytic agents, thromboxane A2 levels rise." When endothelial cells are treated with this prostanoid, their microfilaments become disassembled, reducing junctional membrane apposition and increasing permeability. 12 Other substances, such as histamine, an inflammatory agent, can also cause microfilament disassembly.'134 By contrast, serotonin and norepinephrine cause stabilization of microfilaments and prevent extravasation of red blood cells and petechiae formation in experimental thrombocytopenia." [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Other cell types in the vasculature can release cytokines upon stimulation that can alter vascular permeability. Interleukin (monocytic) and leukotriene (lymphocytic) cytokines can each produce an increase in albumin leakage into tissue.18-20 Other leukocytic factors such as tumor necrosis factor, platelet-activating factor,21 and interferons can have similar effects on vascular permeability.18 '20'22 In addition, plasmin generation may lead to a functional state of thrombocytopenia. We have shown that infusion of thrombolytic agents22 produces a biphasic effect on platelet function -an early stimulatory phase and a later inhibitory phase. Adjunctive therapy with an antiplatelet agent prevents the early increase in aggregation response while prolonging the later decrease in aggregation response. The inhibitory phase may lead to events similar to those seen in thrombocytopenia that result in a net increase in vascular permeability. As 
Limitations
We recognize that these experiments do not prove that the accumulation of albumin in the perivascular or extravascular space occurs solely through a direct increase in endothelial permeability. There are other factors, such as intravascular and tissue pressures, lymph flow, and numbers of perfused capillaries, that may also be important in our observations. To address the issue of blood volume or perfused capillary density, we perfused saline through the artery immediately after the last tissue sampling and removed an adjacent tissue segment. We found no significant difference in the tissue counts before and after saline washout, suggesting that a change in blood volume is an unlikely explanation for our results. We did not extensively address all of the other potential factors in these experiments, but we did measure lymph flow in several animals treated with t-PA and found it to be increased. However, more experiments are needed to determine adequately the role of each of these parameters in our study.
We recently performed in vitro studies that suggest that plasmin generation can directly alter endothelial monolayer permeability.30 In a tissue culture system, we have shown that radioactive albumin passage across a monolayer of endothelial cells is directly correlated with plasmin activity. This suggests that our results may be the consequence of a direct increase in vascular permeability.
Summary
We have demonstrated that therapeutic doses of t-PA lead to an increase in vascular permeability and that this increase in permeability is positively correlated with bleeding time and plasmin activity. These observations suggest that the bleeding diathesis associated with thrombolytic therapy may be due in part to a compromise of vessel wall integrity. This effect of thrombolytic therapy and its reversal by DDAVP provide new and potentially useful information for the optimal management of patients receiving thrombolytic agents.
